SynthesisBritish journal of cancer2011
Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis.
Synthesis in British journal of cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Systemic Lupus Erythematosus Associated with Ovarian Cancer.Internal medicine (Tokyo, Japan) · 2019Pooled it
- The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis.Arthritis research & therapy · 2018Pooled it
- No association between the risk of breast cancer and systemic lupus erythematosus: evidence from a meta-analysis.Clinical rheumatology · 2018Pooled it
- EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome.Annals of the rheumatic diseases · 2017Guideline
- A systematic review of the epidemiological literature on the risk of urological cancers in systemic lupus erythematosus.Journal of cancer research and clinical oncology · 2014Pooled it
- Female cancer incidence before and after diagnosis of primary Sjögren's disease: A retrospective cohort study.Journal of translational autoimmunity · 2026Article
- Cancer incidence and the influence of immunosuppressive agents in Korean patients with systemic lupus erythematosus: a retrospective cohort study.Arthritis research & therapy · 2025Article
- Genetic Causal Relationship Between Systemic Lupus Erythematosus and Malignant Tumors of the Female Reproductive System: A GWAS Analysis in European Populations.Human mutation · 2025Article
- A bidirectional Mendelian randomization analysis of the causal relationship between inflammatory bowel disease and breast cancer based on estrogen receptor status.Discover oncology · 2024Article
- Malignancy in systemic lupus erythematosus: relation to disease characteristics in 92 patients - a single center retrospective study.Rheumatology international · 2024Article
- Causality between autoimmune diseases and breast cancer: a two-sample Mendelian randomization study in a European population.Discover oncology · 2024Article
- Association between systemic lupus erythematosus and common female reproductive system malignancies.Discover oncology · 2024Article
- Causal effects of autoimmune diseases on thyroid cancer: a two-sample Mendelian randomization study.Frontiers in endocrinology · 2024Article
- Exploring the Molecular Mechanisms and Shared Gene Signatures Between Systemic Lupus Erythematosus and Bladder Urothelial Carcinoma.International journal of general medicine · 2024Article
- The interconnected roles of TRIM21/Ro52 in systemic lupus erythematosus, primary Sjögren's syndrome, cancers, and cancer metabolism.Cancer cell international · 2023Review
- Survival in elderly patients with breast cancer with and without autoimmune disease.Cancer medicine · 2023Article
- Recurrent Non-Lactational Fungal Abscesses in a Systemic Lupus Erythematosus Patient: Causation or Mere Association? A Case Report and Literature Review.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2022Review
- The risk of cancer in patients with primary Sjögren syndrome: a single-center study from Turkey.Turkish journal of medical sciences · 2022Article
- Review
- A ceRNA regulatory network in systemic lupus erythematosus and its molecular interplay with cancer.Annals of translational medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAn increased lymphoma risk is well documented in systemic lupus (SLE). Less attention has been focused on women's cancers, even though SLE affects mostly females. Our objective was to estimate the risk of breast, ovarian, and endometrial cancers in SLE, relative to the general population.
methodsData were included from five recent studies of large SLE cohorts. The number of cancers observed was determined for each cancer type. The expected number of malignancies was ascertained from general population data. The parameter of interest was the standardised incidence ratio (SIR), the ratio of observed to expected malignancies.
resultsThe five studies included 47,325 SLE patients (42,171 females) observed for 282,553 patient years. There were 376 breast cancers, 66 endometrial cancers, and 44 ovarian cancers. The total number of cancers observed was less than that expected, with SIRs of 0.76 (95% CI: 0.69, 0.85) for breast cancer, 0.71 (95% CI: 0.55, 0.91) for endometrial cancer, and 0.66 (95% CI: 0.49, 0.90) for ovarian cancer.
conclusionsData strongly support a decreased risk of breast, ovarian, and endometrial cancers in SLE. This may be due to inherent differences in women in SLE (vs the general population) regarding endogenous oestrogen, other medications, and/or genetic make-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.